We are live on
!
Find out more
BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Est. Return
64.18%
This Fund
S&P 500
This Quarter
Est. Return
+19.22%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$285M
AUM Growth
+$60.8M
(+27%)
Cap. Flow
+$35.3M
Cap. Flow
% of AUM
12.39%
Top 10 Holdings %
Top 10 Hldgs %
55.03%
Holding
34
New
11
Increased
9
Reduced
1
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$16.1M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$14.6M |
| 3 |
AKRX
Akorn Inc
AKRX
|
+$13.6M |
| 4 |
United Therapeutics
UTHR
|
+$11.4M |
| 5 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$12.5M |
| 2 |
Smith & Nephew
SNN
|
+$12.5M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$11.1M |
| 4 |
Biogen
BIIB
|
+$11M |
| 5 |
Molina Healthcare
MOH
|
+$9.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.64% |
| 2 | Miscellaneous | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $18.1M | 6.36% |
110,000
+10,000
| +10% | +$1.27M |
|
2
Centene
CNC
$33.1B
| $17.7M | 6.2% |
500,000
+40,000
| +9% | +$1.2M |
|
|
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $16.5M | 5.78% |
130,000
+30,000
| +30% | +$3.43M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $16.2M | 5.67% |
67,500
+20,000
| +42% | +$4.6M |
|
5
Viatris
VTRS
$19.4B
| $16M | 5.62% |
270,000
+75,000
| +38% | +$4.28M |
|
|
ENDP
6
DELISTED
Endo International plc
ENDP
| $15.7M | 5.51% |
+175,000
| New | +$14.6M |
|
|
7
Alkermes
ALKS
$7.73B
| $14.3M | 5.03% |
+235,000
| New | +$16.1M |
|
|
AKRX
8
DELISTED
Akorn Inc
AKRX
| $14.3M | 5% |
+300,000
| New | +$13.6M |
|
9
Edwards Lifesciences
EW
$51.8B
| $14.2M | 5% |
600,000
+240,000
| +67% | +$5.38M |
|
10
Intuitive Surgical
ISRG
$130B
| $13.9M | 4.87% |
247,500
+130,500
| +112% | +$7.39M |
|
|
IPXL
11
DELISTED
Impax Laboratories, Inc.
IPXL
| $13.4M | 4.69% |
+285,000
| New | +$11.3M |
|
|
12
United Therapeutics
UTHR
$20.9B
| $12.9M | 4.54% |
+75,000
| New | +$11.4M |
|
13
Teva Pharmaceuticals
TEVA
$42.4B
| $12.8M | 4.48% |
205,000
+25,000
| +14% | +$1.45M |
|
14
Vertex Pharmaceuticals
VRTX
$138B
| $12.4M | 4.35% |
105,000
+37,500
| +56% | +$4.49M |
|
|
CPHD
15
DELISTED
Cepheid Inc
CPHD
| $11.4M | 3.99% |
+200,000
| New | +$11.2M |
|
16
Cooper Companies
COO
$13.6B
| $11.2M | 3.95% |
240,000
-60,000
| -20% | -$2.53M |
|
17
Jazz Pharmaceuticals
JAZZ
$16B
| $11.2M | 3.94% |
+65,000
| New | +$11.2M |
|
18
Elevance Health
ELV
$88.4B
| $11.2M | 3.93% |
+72,500
| New | +$10.3M |
|
|
ALR
19
DELISTED
Alere Inc
ALR
| $11M | 3.86% |
+225,000
| New | +$9.87M |
|
20
BioMarin Pharmaceuticals
BMRN
$12.9B
| $10.9M | 3.83% |
+87,500
| New | +$9.27M |
|
|
ESRX
21
DELISTED
Express Scripts Holding Company
ESRX
| $9.76M | 3.42% |
+112,500
| New | +$9.44M |
|
|
22
Biogen
BIIB
$32.6B
| – | – |
-32,500
| Closed | -$11M |
|
23
Globus Medical
GMED
$10.5B
| – | – |
-275,000
| Closed | -$6.54M |
|
24
Humana
HUM
$48.2B
| – | – |
-62,500
| Closed | -$8.98M |
|
|
25
Molina Healthcare
MOH
$10.5B
| – | – |
-180,000
| Closed | -$9.63M |
|
Similar funds
BCM
RJA
RP
ACPVT
SFA
KL
AIM
KFS
Blue Jay Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Blue Jay Capital Management held 34 positions worth $285M, up 27% from $224M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Blue Jay Capital Management deployed $35.3M of net new capital in Q1 2015, opening 11 new positions and adding to 9 existing holdings. Its largest new stake was Alkermes: 235,000 shares worth $14.3M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 84% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cooper Companies, an estimated $2.53M trimmed.
- Blue Jay Capital Management's largest Q1 2015 buy was Alkermes: 235,000 shares worth $14.3M.
- Blue Jay Capital Management added most to Intuitive Surgical in Q1 2015, an estimated $7.39M increase.
- Blue Jay Capital Management's biggest Q1 2015 reduction was Cooper Companies, cutting an estimated $2.53M.
- Blue Jay Capital Management fully exited Perrigo in Q1 2015, selling an estimated $12.5M.
- Blue Jay Capital Management's ten largest holdings make up 55% of its $285M portfolio in Q1 2015.
- Blue Jay Capital Management opened 11 new positions and closed 13 in Q1 2015.
- Blue Jay Capital Management's portfolio value rose 27% quarter-over-quarter to $285M.
Based on Blue Jay Capital Management's 13F filing for Q1 2015, filed 13 May 2015.